Back to top
more

AMAG Pharmaceuticals, Inc. (AMAG)

(Delayed Data from NSDQ)

$11.57 USD

11.57
544,003

+0.34 (3.03%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.57 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Palatin (PTN) to Report Q2 Earnings: What's in the Cards?

Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.

AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: Should You Buy?

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG (AMAG) to be Acquired by Covis Group for $647 Million

AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.

AMAG Pharmaceuticals (AMAG) Down 0.4% Since Last Earnings Report: Can It Rebound?

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade

AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Lags Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 16.67% and -6.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is AMAG Pharmaceuticals (AMAG) Up 6.8% Since Last Earnings Report?

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues

AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.

AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Tops Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: What to Know Ahead of Q1 Release

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG Pharmaceuticals (AMAG) Down 21.5% Since Last Earnings Report: Can It Rebound?

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day

LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day

Indrajit Bandyopadhyay headshot

3 Drugmakers Still Worth Betting on Amid Coronavirus Woes

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade

AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.

AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Tops Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -2.94% and 1.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Proteostasis (PTI) to Report Q4 Earnings: What's in Store?

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

Is a Surprise Coming for AMAG This Earnings Season?

AMAG is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

What in Store for Universal Health's (UHS) Q4 Earnings?

Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.

NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?

We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.

AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?

During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.

Teladoc (TDOC) to Post Q4 Earnings: What's in the Cards?

Teladoc's (TDOC) Q4 performance is likely to have benefited from increased membership and visits.